other material
confidence high
sentiment positive
materiality 0.70
Elicio reports 84% CD8+ T cell response and antigen spreading in ELI-002 Phase 1 at AACR
Elicio Therapeutics, Inc.
- 68% of patients developed cytotoxic mKRAS-specific CD4+ T cells; 84% developed CD8+ T cells.
- Majority of patients showed antigen spreading: T cells targeted additional patient-specific tumor mutations beyond mKRAS.
- Booster doses maintained/increased mKRAS-specific T cell response with increased memory phenotype; no regulatory T cell response detected.
- Preclinical ELI-007 and ELI-008 showed 42-fold to several-hundred-fold increased immune response vs. conventional vaccines.
- Initial clinical data for ELI-002 7P expected in Q2 2024.